Medication info
Amosartan Q Tablets 5/100/5 mg (Amlodipine, Losartan, Rosuvastatin)

Amosartan Q Tablets 5/100/5 mg (Amlodipine, Losartan, Rosuvastatin)

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Camsylate›7.84mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tabletLosartan Potassium›100mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Pale yellow-brown oval film-coated tablets
Packaging
30 tablets/bottle, 100 tablets/bottle, 30 tablets/box [10 tablets/PTPx3]
Approval status
Active

MFDS item code 201705687 · Approved 2017.07.14 · Insurance code 643507870

Summary

Main use
Improves hypertension and dyslipidemia and suppresses the progression of atherosclerosis and the risk of cardiovascular disease
Who takes it
Adults
Adult dose
This medicine should be administered only to adults. The dosage should be individualized for each patient based on the efficacy and tolerability of the amlodipine/losartan combination and rosuvastatin. ○ Amlodipine/losartan combination The recommended dosage of the amlodipine/losartan combination is 1 tablet once daily in adults, taken with water, with or without food. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). Before administering the amlodipine/losartan combination, it is recommended that the dosage of the individual component (amlodipine or losartan) be adjusted. However, if blood pressure is not controlled with monotherapy using the individual components, a direct switch to the amlodipine/losartan combination may be considered as follows. - 5/50 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or losartan 50 mg monotherapy. - 5/100 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or losartan 100 mg monotherapy. Before administering the amlodipine/losartan combination as initial therapy to patients with stage 2 hypertension, the decision to administer it should take into consideration baseline blood pressure, target blood pressure, and the expected degree of achievement of the treatment goal with the combination compared with the individual agents. This medicine is usually administered at 5/50 mg once daily. If blood pressure is not adequately controlled after 2 weeks of treatment, the dose may be increased to 10/50 mg once daily. ○ Patients with renal impairment: No dosage adjustment is required in patients with mild renal impairment (e.g., creatinine clearance 20∼50 mL/min). However, administration of the amlodipine/losartan combination is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. ○ Patients with reduced intravascular volume: Administration of the amlodipine/losartan combination is not recommended in a small number of patients with reduced intravascular volume (e.g., patients receiving treatment with high doses of diuretics). (See section 1. Warnings under Precautions for Use.) ○ Patients with hepatic impairment: Administration of the amlodipine/losartan combination is not recommended in patients with a history of hepatic impairment who require a reduced dose of losartan (e.g., 25 mg once daily). ○ Older adults: In older adults aged 75 years or older, an initial dose of losartan of 25 mg once daily is recommended; therefore, administration of the amlodipine/losartan combination as initial therapy is not recommended. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose in adults is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 mg daily. 2. Older adults: No dosage adjustment is required. 3. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or below, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. Patients taking the amlodipine/losartan combination together with rosuvastatin may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Improves hypertension and dyslipidemia and suppresses the progression of atherosclerosis and the risk of cardiovascular disease

  • Essential hypertension
  • stage 2 hypertension
  • hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • stroke risk
  • myocardial infarction risk
  • vascular revascularization risk
View approved original text

This medication is used for patients who need to take amlodipine/losartan combination therapy along with rosuvastatin. The amlodipine/losartan combination is suitable for the initial treatment of patients with essential hypertension who find it difficult to control blood pressure with monotherapy or for stage 2 hypertension patients. On the other hand, rosuvastatin is used as an adjunct in cases of hypercholesterolemia and mixed dyslipidemia, especially when diet alone does not control it, and helps delay the progression of atherosclerosis. Additionally, this medication is effective in reducing the risk of stroke, myocardial infarction, and vascular revascularization in high-risk cardiovascular patients. Therefore, this medication is used to improve the treatment of patients with both hypertension and hypercholesterolemia.

How to take

Adult dose

This medicine should be administered only to adults. The dosage should be individualized for each patient based on the efficacy and tolerability of the amlodipine/losartan combination and rosuvastatin. ○ Amlodipine/losartan combination The recommended dosage of the amlodipine/losartan combination is 1 tablet once daily in adults, taken with water, with or without food. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). Before administering the amlodipine/losartan combination, it is recommended that the dosage of the individual component (amlodipine or losartan) be adjusted. However, if blood pressure is not controlled with monotherapy using the individual components, a direct switch to the amlodipine/losartan combination may be considered as follows. - 5/50 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or losartan 50 mg monotherapy. - 5/100 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or losartan 100 mg monotherapy. Before administering the amlodipine/losartan combination as initial therapy to patients with stage 2 hypertension, the decision to administer it should take into consideration baseline blood pressure, target blood pressure, and the expected degree of achievement of the treatment goal with the combination compared with the individual agents. This medicine is usually administered at 5/50 mg once daily. If blood pressure is not adequately controlled after 2 weeks of treatment, the dose may be increased to 10/50 mg once daily. ○ Patients with renal impairment: No dosage adjustment is required in patients with mild renal impairment (e.g., creatinine clearance 20∼50 mL/min). However, administration of the amlodipine/losartan combination is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. ○ Patients with reduced intravascular volume: Administration of the amlodipine/losartan combination is not recommended in a small number of patients with reduced intravascular volume (e.g., patients receiving treatment with high doses of diuretics). (See section 1. Warnings under Precautions for Use.) ○ Patients with hepatic impairment: Administration of the amlodipine/losartan combination is not recommended in patients with a history of hepatic impairment who require a reduced dose of losartan (e.g., 25 mg once daily). ○ Older adults: In older adults aged 75 years or older, an initial dose of losartan of 25 mg once daily is recommended; therefore, administration of the amlodipine/losartan combination as initial therapy is not recommended. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose in adults is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 mg daily. 2. Older adults: No dosage adjustment is required. 3. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or below, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. Patients taking the amlodipine/losartan combination together with rosuvastatin may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so pregnant women or women who may become pregnant should not take it. Patients with low blood volume, such as those taking diuretics, need to be careful when initially using this medication, as there is a risk of too low blood pressure. Patients allergic to any component of this medication, those with certain genetic disorders, or those with severe liver or kidney dysfunction should avoid taking it. Elderly patients, those with hyperkalemia, liver or heart problems, and those with a history of myopathy should use this medication cautiously and may require regular monitoring. This medication can cause muscle pain, muscle weakness, and rarely serious muscle damage. If any unusual symptoms occur in the muscles, consult a doctor immediately. This medication may affect liver function; therefore, regular liver function tests should be conducted, and if symptoms of liver damage occur, discontinue use immediately. Interactions may occur when taken with other drugs. It is essential to inform the healthcare provider of all medications being taken, especially caution is needed with potassium-sparing diuretics, specific antibiotics, antifungals, and immunosuppressants. Pregnant or breastfeeding women should not take this medication, and if breastfeeding, it should be discussed with medical personnel since it can be passed into breast milk. While using this medication, blood pressure, kidney function, electrolyte levels, etc., should be monitored regularly to check for abnormalities, and any changes in symptoms should be reported to healthcare providers immediately. Additionally, this medication contains lactose, so patients with lactose intolerance should not take it, and it is advisable to avoid alcohol while taking this medication.

Side effects

Craniosynostosis, anuria, hypotension, renal failure, upper respiratory tract infection, dizziness, dyspepsia, lower gastrointestinal bleeding, orthostatic dizziness, syncope, rhabdomyolysis, pancreatic adenocarcinoma, dizziness, headache, drowsiness, cerebral infarction, weakness, chest discomfort, chest pain, early satiety, peripheral edema, pitting edema, abdominal discomfort, nausea, gastroesophageal reflux disease, constipation, pruritus, urticaria, palpitations, flushing, orthostatic hypotension, facial flushing, dyspnea, cough, conjunctival injection, increased micturition, angioedema, diabetes mellitus, constipation, nausea, abdominal pain, pancreatitis, rash, myalgia, myopathy, weakness, polyneuropathy, amnesia, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, eosinophilia and systemic symptoms associated drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, interstitial lung disease, sexual dysfunction, gynecomastia, ALT increase, chest pain, myalgia, CK increase, dizziness, AST increase, weakness, arthralgia, fatigue, numbness, paresthesia, chest discomfort, anorexia, abdominal distension, abnormal liver function tests, syncope, generalized pain, muscle cramping, gout, erectile dysfunction, vasculitis, weakness, lethargy, weight gain, weight loss, tension, sensory loss, paresthesia, peripheral neuropathy, taste disturbance, tremor, extrapyramidal disorder, erectile dysfunction, gynecomastia, changes in bowel habits, dry mouth, gastritis, gingival hyperplasia, pancreatitis, vomiting, hyperglycemia, arthralgia, low back pain, muscle cramping, leukopenia, thrombocytopenia, insomnia, mood changes, rhinitis, hair loss, hyperhidrosis, purpura, skin discoloration, toxic epidermal necrolysis, tinnitus, visual disturbances, increased frequency of urination, urinary disorders, nocturia, hepatitis, jaundice, elevated liver enzymes, erythematous rash, maculopapular rash, heaviness, heat sensation, impaired glucose tolerance, weakness, myocardial infarction, arrhythmia, chest pain, hypotension, sinus block, atrioventricular block, abdominal discomfort, precordial pain, diarrhea, loose stools, constipation, flushing, severe liver dysfunction, acute renal failure, elevated blood creatinine, hypoglycemia, angioedema, vasculitis, anaphylactic-like syndrome, lethargy, anemia, thrombocytopenia, myalgia, weakness, elevation of creatine kinase, taste disturbance, dry cough, erythema, hyperkalemia, hyponatremia, acute hepatitis, fulminant hepatitis, ventricular ectopy, atrial fibrillation, hypoglycemia, headache, dizziness, drowsiness, weakness, chest pain, fever, influenza-like illness, hypotension, orthostatic hypotension, diarrhea, dyspepsia, diabetic nephropathy, cataract, anemia, hyperkalemia, low back pain, leg pain, knee pain, myasthenia, sensory impairment, bronchitis, congestion, upper respiratory tract infection, sinusitis, nausea, cough, sinus dysfunction, pharyngitis, myalgia, insomnia, headache, weakness, edema, abdominal pain, chest pain, facial edema, fever, syncope, angina, cerebrovascular accident, myocardial infarction, atrial fibrillation, palpitations, bradycardia, tachycardia, ventricular tachycardia, anorexia, toothache, dry mouth, anemia, gout, upper limb pain, joint swelling, knee pain, musculoskeletal pain, shoulder pain, muscle stiffness, arthralgia, arthritis, fibromyalgia, myasthenia, anxiety, ataxia, confusion, depression, nightmares, sensory impairment, reduced libido, memory impairment, migraine, nerve irritability, paresthesia, peripheral neuropathy, panic disorder, sleep disorder, tremor, dizziness, dyspnea, bronchitis, pharyngitis discomfort, epistaxis, rhinitis, respiratory congestion, chest discomfort, hair loss, dermatitis, dry skin, petechial hemorrhage, erythema, flushing, photosensitivity reaction, pruritus, rash, sweating, urticaria, blurred vision, burning sensation and pain in the eyes, conjunctivitis, taste disturbance, tinnitus, visual impairment, erectile dysfunction, nocturia, increased urination, urethral infection, angioedema, vasculitis, anaphylactic-like syndrome, abnormal liver function, intestinal vascular edema, lethargy, anemia, thrombocytopenia, myalgia, weakness, elevation of creatine kinase, rhabdomyolysis, taste disturbance, dry cough, erythema, hyperkalemia, hyponatremia, acute hepatitis, fulminant hepatitis, renal failure, ventricular ectopy, atrial fibrillation, hypoglycemia, syncope, loss of consciousness, hypotension, decreased effective blood volume, blood pressure reduction at low doses, increased serum creatinine, elevated serum potassium, increased serum potassium levels, increased serum creatinine levels, increased serum potassium concentration, increased serum creatinine concentration, elevated serum potassium levels, increased serum creatinine levels, increased serum potassium levels, increased serum creatinine levels, increased serum potassium levels, increased serum creatinine levels, increased serum potassium levels, increased serum creatinine levels, increased serum potassium levels, increased serum creatinine levels, increased serum potassium levels, increased serum creatinine levels, increased serum potassium levels, increased serum creatinine levels, increased serum potassium levels, increased serum creatinine levels, increased serum potassium levels, increased serum creatinine levels, increased serum potassium levels, increased serum creatinine levels

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container protected from air and moisture. It is essential to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pale yellow-brown oval film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle, 30 tablets/box [10 tablets/PTPx3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.